PIERI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.320
EU - Europa 4.899
AS - Asia 2.062
SA - Sud America 278
AF - Africa 60
OC - Oceania 51
Totale 13.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.271
PL - Polonia 2.220
RU - Federazione Russa 1.093
SG - Singapore 548
IT - Italia 423
CN - Cina 422
HK - Hong Kong 332
IE - Irlanda 270
SE - Svezia 270
VN - Vietnam 264
BR - Brasile 219
KR - Corea 179
DE - Germania 140
FR - Francia 115
FI - Finlandia 105
GB - Regno Unito 80
IN - India 77
CH - Svizzera 75
AU - Australia 49
JP - Giappone 42
TR - Turchia 32
CA - Canada 31
ID - Indonesia 27
BD - Bangladesh 26
JO - Giordania 22
UA - Ucraina 21
AE - Emirati Arabi Uniti 20
ES - Italia 17
IQ - Iraq 17
NL - Olanda 16
AR - Argentina 14
BE - Belgio 14
AT - Austria 13
CI - Costa d'Avorio 12
CO - Colombia 12
PK - Pakistan 11
ZA - Sudafrica 11
EC - Ecuador 9
EG - Egitto 8
MA - Marocco 8
MX - Messico 8
PE - Perù 6
PY - Paraguay 5
VE - Venezuela 5
CL - Cile 4
DZ - Algeria 4
IR - Iran 4
KE - Kenya 4
NP - Nepal 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
UY - Uruguay 4
UZ - Uzbekistan 4
AL - Albania 3
AZ - Azerbaigian 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
NG - Nigeria 3
RO - Romania 3
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
QA - Qatar 2
RS - Serbia 2
SC - Seychelles 2
SV - El Salvador 2
TH - Thailandia 2
TW - Taiwan 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
MY - Malesia 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UG - Uganda 1
Totale 13.670
Salva come PNG Salva come JPEG
Città #
Warsaw 2.214
Santa Clara 1.295
Fairfield 747
Ashburn 655
Singapore 346
Woodbridge 329
Seattle 308
Chandler 279
Hong Kong 271
Dublin 269
Houston 259
Wilmington 246
Cambridge 245
Seoul 172
San Jose 161
Ann Arbor 148
Beijing 116
Altamura 109
Lawrence 108
Ho Chi Minh City 86
Florence 84
Princeton 81
Boston 73
Bern 72
Buffalo 70
Hanoi 65
Lauterbourg 60
Jacksonville 53
Dallas 52
New York 50
Los Angeles 49
Mumbai 48
Munich 48
Moscow 44
San Diego 38
Melbourne 34
Boardman 32
The Dalles 31
Dong Ket 30
Helsinki 30
Council Bluffs 29
Bremen 28
Shanghai 28
Jakarta 24
Hefei 23
São Paulo 23
Izmir 22
Phoenix 22
Medford 21
Paris 20
Tokyo 20
Abu Dhabi 19
London 17
Rome 17
Clifton 15
Norwalk 15
Redondo Beach 15
Kent 14
Abidjan 12
Brussels 12
Chicago 12
Frankfurt am Main 12
Sydney 12
Vienna 12
Guangzhou 11
Montreal 11
Turku 11
Barcelona 10
Hillsboro 10
Toronto 10
Dearborn 9
Milan 9
Orem 9
Toyooka 9
Da Nang 8
Denver 8
Andover 7
Brasília 7
Brooklyn 7
Haiphong 7
Manchester 7
Pune 7
Rio de Janeiro 7
Tianjin 7
Amsterdam 6
Parnaiba 6
Poplar 6
Słupsk 6
West Jordan 6
Yubileyny 6
Alexandria 5
Atlanta 5
Baghdad 5
Curitiba 5
Elk Grove Village 5
Johannesburg 5
Ninh Bình 5
San Francisco 5
Ahmedabad 4
Cagliari 4
Totale 10.106
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 429
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 380
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 330
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 330
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 325
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 321
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 317
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 307
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 299
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 299
Imaging studies in extramedullary hematopoiesis of the spleen 295
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 295
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 288
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms 283
Chronic myeloproliferative neoplasms: a collaborative approach. 281
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 279
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 274
MPN Score 250
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 240
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 228
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 209
Mutations and prognosis in primary myelofibrosis. 193
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 190
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 189
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 187
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience 178
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution 178
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 176
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 175
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 175
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 175
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 172
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 172
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 169
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 166
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 165
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. 163
Treatment options for essential thrombocythemia and polycythemia vera 163
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 160
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 160
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 159
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 159
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 158
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 158
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 157
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 150
Risk of second cancers in chronic myeloproliferative neoplasms. 150
Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B 150
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 149
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 149
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 144
Prognotic Impact of Mutations in Systemic Mastocytosis 144
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. 137
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 137
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 135
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 135
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 129
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 128
Risk of second cancers in chronic myeloproliferative neoplasms 125
Rationale for combination therapies in myelofibrosis 125
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 119
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. 116
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. 115
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics. 109
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 109
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 108
Masked polycythemia vera (mPV): results of an international study. 101
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. 100
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 96
Policitemia Vera. per conoscerla meglio. 95
Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center 93
Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery? 60
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 56
Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes 49
null 10
Totale 13.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.450
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021142 0 0 0 0 0 0 0 0 0 0 73 69
2021/2022488 14 48 48 16 13 19 20 39 27 26 76 142
2022/20231.353 121 289 68 111 94 216 160 66 102 15 34 77
2023/2024519 16 46 76 22 46 72 17 110 10 31 46 27
2024/20253.372 90 319 210 478 1.063 522 71 121 205 86 96 111
2025/20262.752 387 404 215 187 345 127 403 155 200 210 119 0
Totale 13.779